{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:41:29Z","timestamp":1780933289011,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.canrad.2023.08.001","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T12:19:10Z","timestamp":1698322750000},"page":"768-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021\u20132023"],"prefix":"10.1016","volume":"27","author":[{"given":"J.","family":"Boustani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.08.001_bib0185","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0190","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ijrobp.2021.07.045","article-title":"Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: multicenter phase 2\/3 randomized trial CONCORDE (PRODIGE-26)","volume":"111","author":"Cr\u00e9hange","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.001_bib0195","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","article-title":"A phase III multicenter randomized clinical trial of 60Gy versus 50Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2023.08.001_bib0200","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van\u00a0Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.001_bib0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.001_bib0210","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.08.001_bib0215","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.001_bib0220","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.08.001_bib0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1470-2045(21)00718-X","article-title":"Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology\/RTOG 1010): a multicentre, randomised, phase 3 trial","volume":"23","author":"Safran","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","author":"Parikh","year":"20231174799","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.001_bib0235","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0240","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2023.08.001_bib0245","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1200\/JCO.2023.41.4_suppl.489","article-title":"NRG\/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC)","volume":"41","author":"Dawson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0250","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2003.09.032","article-title":"Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group","volume":"40","author":"Bosset","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2023.08.001_bib0255","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/annonc\/mdx351","article-title":"Late toxicities and clinical outcome at 5 years of the ACCORD 12\/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer","volume":"28","author":"Azria","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0260","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdu147","article-title":"Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (xelox) versus control","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0265","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdu560","article-title":"Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial","volume":"26","author":"Breugom","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0270","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0275","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0280","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery - a five-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.canrad.2023.08.001_bib0285","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2023.02.027","article-title":"Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial","volume":"185","author":"Bahadoer","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2023.08.001_bib0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.radonc.2020.03.011","article-title":"Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial","volume":"147","author":"van der\u00a0Valk","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0295","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.001_bib0300","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.23.00903","article-title":"Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048)","volume":"41","author":"Basch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0305","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/bjs.10306","article-title":"Network meta-analysis of protocol-driven care and laparoscopic surgery for colorectal cancer","volume":"103","author":"Currie","year":"2016","journal-title":"Br J Surg"},{"key":"10.1016\/j.canrad.2023.08.001_bib0310","first-page":"991","article-title":"Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial","volume":"7","author":"Feng","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.08.001_bib0315","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/DCR.0000000000000862","article-title":"Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection - a matched-controlled study","volume":"60","author":"Hupkens","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.canrad.2023.08.001_bib0320","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S1470-2045(15)00215-6","article-title":"Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial","volume":"16","author":"Garcia-Aguilar","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0325","first-page":"465","article-title":"Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial","volume":"5","author":"Rullier","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.08.001_bib0330","first-page":"356","article-title":"Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial","volume":"8","author":"Gerard","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.08.001_bib0335","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0340","first-page":"825","article-title":"Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis","volume":"3","author":"Chadi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.08.001_bib0345","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(20)30557-X","article-title":"Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study","volume":"22","author":"Fernandez","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0350","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fonc.2019.00318","article-title":"Organ preservation in rectal cancer: the patients\u2019 perspective","volume":"9","author":"Gani","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0355","first-page":"2363","article-title":"Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.001_bib0360","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.1016\/j.ijrobp.2016.06.1006","article-title":"The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus","volume":"96","author":"Sebag-Montefiore","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823002135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823002135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:37:58Z","timestamp":1761136678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823002135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1278321823002135"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.08.001","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021\u20132023","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}